Merck KGaA (OTCMKTS:MKGAY) Given Average Rating of “Buy” by Analysts

Shares of Merck KGaA (OTCMKTS:MKGAYGet Rating) have received a consensus recommendation of “Buy” from the seven analysts that are presently covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $252.50.

MKGAY has been the topic of several research analyst reports. JPMorgan Chase & Co. lowered their price target on Merck KGaA from €270.00 ($290.32) to €250.00 ($268.82) and set an “overweight” rating on the stock in a research report on Monday, March 14th. UBS Group upgraded Merck KGaA from a “sell” rating to a “neutral” rating in a research report on Monday, February 28th.

MKGAY remained flat at $$38.36 during trading hours on Monday. Merck KGaA has a 52 week low of $32.53 and a 52 week high of $42.02. The business’s 50 day simple moving average is $38.36 and its two-hundred day simple moving average is $38.36.

Merck KGaA Company Profile (Get Rating)

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate and Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility.

See Also

Analyst Recommendations for Merck KGaA (OTCMKTS:MKGAY)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.